Apixaban Shows Lower Bleeding Risk vs. Rivaroxaban for VTE

For individuals recovering from venous thromboembolism – blood clots that travel to the lungs or form in deep veins – a new analysis confirms that apixaban is associated with a significantly lower risk of bleeding compared to rivaroxaban. The findings, published March 12, 2026, in The New England Journal of Medicine, offer crucial insight into the safety profiles of these commonly prescribed anticoagulants.

Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), requires prompt treatment with blood thinners to prevent further clot formation. Direct oral anticoagulants (DOACs) like apixaban and rivaroxaban have grow mainstays of this treatment, but until now, a clear understanding of their relative bleeding risks has been lacking, leaving clinicians without definitive guidance on which to prioritize.

COBRRA Trial Findings: A Closer Look

The research, conducted as part of the Comparison of Bleeding Risk between Rivaroxaban and Apixaban (COBRRA) trial, involved 2,760 patients experiencing acute symptomatic pulmonary embolism or proximal deep vein thrombosis. Participants were randomly assigned to receive either rivaroxaban or apixaban for a three-month period. The primary outcome measured was clinically relevant bleeding – encompassing both major and non-major bleeding events.

The results demonstrated a substantial difference in bleeding risk. Clinically relevant bleeding occurred in 3.3% of patients treated with apixaban, compared to 7.1% of those treated with rivaroxaban. This translates to a relative risk ratio of 0.46, favoring apixaban (95% CI, 0.33-0.65; P < .001). Even as medication adherence was higher in the rivaroxaban group (75.1% vs. 65.7% for apixaban), the study did not fully explain the observed difference in bleeding rates.

Importantly, rates of all-cause death and serious adverse events unrelated to bleeding or VTE were similar between the two groups, suggesting that the observed benefit of apixaban regarding bleeding risk did not come at the expense of other safety outcomes. Researchers reported all-cause death in 0.1% of the apixaban group and 0.3% of the rivaroxaban group (RR = 0.25; 95% CI, 0.03-2.26).

Understanding the Implications for Patients and Clinicians

These findings are particularly relevant given that clinical guidelines currently recommend either apixaban or rivaroxaban for the initial three months of VTE treatment. As News-Medical.net reports, the COBRRA trial provides compelling evidence to support a more nuanced approach to anticoagulant selection. The lower bleeding risk associated with apixaban may be especially significant for patients at higher risk of bleeding complications, such as those with a history of gastrointestinal bleeding or kidney disease.

Though, it’s crucial to note that the study does not definitively explain the mechanism behind the observed difference. Researchers speculate that the higher dose of rivaroxaban administered during the first three weeks of treatment may contribute to the increased bleeding risk. Further research is needed to confirm this hypothesis and to explore other potential factors.

Study Design and Limitations

The COBRRA trial was a prospective, randomized, open-label study, meaning that while patients were randomly assigned to treatment groups, both the researchers and participants knew which medication was being administered. To mitigate potential bias, the endpoint assessment was masked, meaning that the individuals evaluating bleeding events were unaware of the treatment assignment. The study population primarily consisted of white men with a mean age of 58, which may limit the generalizability of the findings to other demographic groups.

The researchers also acknowledge that lower adherence to apixaban compared to rivaroxaban could have influenced the results. While the study adjusted for adherence in its analysis, it’s possible that the lower adherence rate partially offset the true benefit of apixaban in reducing bleeding risk. Healio News highlights this point, noting that despite higher adherence to rivaroxaban, the bleeding risk remained significantly lower with apixaban.

What Does This Mean in Terms of Risk?

It’s important to contextualize the observed risk reduction. While a 46% reduction in relative risk sounds substantial, the absolute risk difference between the two medications is relatively small. In the apixaban group, 3.3% of patients experienced clinically relevant bleeding, compared to 7.1% in the rivaroxaban group – a difference of 3.8 percentage points. In other words that for every 100 patients treated with apixaban instead of rivaroxaban, approximately 4 fewer patients would be expected to experience a clinically relevant bleeding event.

The Evolving Landscape of VTE Treatment

The COBRRA trial findings are likely to prompt a reevaluation of current clinical practice guidelines for VTE treatment. While the guidelines currently offer no preference between apixaban and rivaroxaban, the evidence now suggests that apixaban may be a safer option, particularly for patients at increased bleeding risk.

Further research is underway to investigate the optimal dosing strategies for both apixaban and rivaroxaban, as well as to identify patient characteristics that may predict individual responses to these medications. Medscape reports that ongoing trials are exploring the potential benefits of personalized anticoagulation approaches based on genetic factors and other biomarkers.

For patients currently taking rivaroxaban, it is not recommended to switch medications without consulting with a healthcare professional. The decision to switch anticoagulants should be made on an individual basis, taking into account the patient’s overall health status, bleeding risk factors, and medication adherence. The most important step is to maintain open communication with your physician to ensure you are receiving the most appropriate and safe treatment for your specific needs.